# Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

> **NCT03567304** · PHASE4 · UNKNOWN · sponsor: **Chiang Mai University** · enrollment: 28 (estimated)

## Conditions studied

- HIV-1-infection
- Neurocognitive Dysfunction

## Interventions

- **DRUG:** Rilpivirine 25 mg

## Key facts

- **NCT ID:** NCT03567304
- **Lead sponsor:** Chiang Mai University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-06
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567304, "Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03567304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*